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IMPORTANCE Nausea and vomiting affects approximately 85% of pregnant women. Themost
severe form, hyperemesis gravidarum, affects up to 3% of women and can have significant
adverse physical and psychological sequelae.
OBJECTIVE To summarize current evidence on effective treatments for nausea and vomiting
in pregnancy and hyperemesis gravidarum.
EVIDENCE REVIEW Databases were searched to June 8, 2016. Relevant websites and
bibliographies were also searched. Titles and abstracts were assessed independently by
2 reviewers. Results were narratively synthesized; plannedmeta-analysis was not possible
because of heterogeneity and incomplete reporting of findings.
FINDINGS Seventy-eight studies (n = 8930 participants) were included: 67 randomized
clinical trials (RCTs) and 11 nonrandomized studies. Evidence from 35 RCTs at low risk of bias
indicated that ginger, vitamin B6, antihistamines, metoclopramide (for mild symptoms),
pyridoxine-doxylamine, and ondansetron (for moderate symptoms) were associated with
improved symptoms compared with placebo. One RCT (n = 86) reported greater
improvements in moderate symptoms following psychotherapy (change in Rhodes score
[range, 0 {no symptoms} to 40 {worst possible symptoms}], 18.76 [SD, 5.48] to 7.06
[SD, 5.79] for intervention vs 19.18 [SD, 5.63] to 12.81 [SD, 6.88] for comparator [P < .001]).
For moderate-severe symptoms, 1 RCT (n = 60) suggested that pyridoxine-doxylamine
combination taken preemptively reduced risk of recurrence of moderate-severe symptoms
compared with treatment once symptoms begin (15.4% vs 39.1% [P < .04]). One RCT (n = 83)
found that ondansetron was associated with lower nausea scores on day 4 than
metoclopramide (mean visual analog scale [VAS] score, 4.1 [SD, 2.9] for ondansetron vs 5.7
[SD, 2.3] formetoclopramide [P = .023]) but not episodes of emesis (5.0 [SD, 3.1] vs 3.3 [SD, 3],
respectively [P = .013]). Although therewas no difference in trend in nausea scores over the
14-day study period, trend in vomiting scoreswas better in the ondansetron group (P = .042).
One RCT (n = 159) found no difference betweenmetoclopramide and promethazine after 24
hours (episodes of vomiting, 1 [IQR, 0-5] formetoclopramide vs 2 [IQR, 0-3] for promethazine
[P = .81], VAS [0-10 scale] for nausea, 2 [IQR, 1-5] vs 2 [IQR, 1-4], respectively [P = .99]). Three
RCTs compared corticosteroidswith placebo or promethazine ormetoclopramide inwomen
with severe symptoms. Improvementswere seen in all corticosteroid groups, but only a
significant difference between corticosteroids vsmetoclopramidewas reported (emesis
reduction, 40.9%vs 16.5% at day 2; 71.6% vs 51.2% at day 3; 95.8%vs 76.6% at day 7 [n = 40,
P < .001]). For other interventions, evidencewas limited.
CONCLUSIONS AND RELEVANCE Formild symptoms of nausea and emesis of pregnancy,
ginger, pyridoxine, antihistamines, andmetoclopramide were associated with greater benefit
than placebo. For moderate symptoms, pyridoxine-doxylamine, promethazine, and
metoclopramide were associated with greater benefit than placebo. Ondansetron was
associated with improvement for a range of symptom severity. Corticosteroids may be
associated with benefit in severe cases. Overall the quality of evidence was low.
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N ausea and vomiting in pregnancy is a common butdebilitating condition affecting up to 85% of women.1Themost severe form, hyperemesis gravidarum, affects
0.3% to 3% of pregnant women and is characterized by intrac-
table vomiting, dehydration, electrolyte imbalance, ketosis, nutri-
tional deficiencies, and weight loss.2 Symptoms usually start by 6
to 8 weeks’ gestation and subside before 20 weeks.1 In severe
cases, women may require prolonged hospitalization and support
from enteral or parenteral nutrition.
Symptoms can affect day-to-day functioning,3 ability to work,4
and interactions with offspring, family, and friends.5 A recent sys-
tematic review andmeta-analysis reported an association between
hyperemesis gravidarum and preterm delivery and small-for-
gestational age infants, although there was no association with
congenital anomalies or perinatal death.6
This article reviews evidence regarding treatments for varying
severity of symptoms of nausea and vomiting in pregnancy or hy-
peremesis gravidarum.
Methods
We searched electronic databases (MEDLINE, EMBASE, CENTRAL,
CDSR, DARE, CINAHL, British Nursing Index, PsycINFO, CAB
Abstracts, LILACS, AMED, Science Citation Index, Social Science
Citation Index, Scopus, Conference Proceedings Index–Science,
ClinicalTrials.gov, NHS-EED, HEED, China National Knowledge
Infrastructure) and key websites for randomized clinical trials
(RCTs) and nonrandomized comparative studies of pharmacologi-
cal or nonpharmacological interventions for nausea and vomiting
in pregnancy or hyperemesis gravidarum, without language restric-
tion, from inception to June 8, 2016, using terms describing
(1) nausea, vomiting, or hyperemesis gravidarum; (2) pregnancy
(see eBox 1 in the Supplement). We also searched for population-
based case series, for estimates of rare adverse events and fetal
outcomes, and for treatments reserved for the most severe cases
of hyperemesis gravidarum.
Titles and abstractswere assessed independently by 2 review-
ers (A.O., C.M.). The full text of each relevant article was reviewed
to further determine eligibility. Major exclusion criteria were stud-
ies with participants recruited after 20weeks’ gestation and those
with no relevant outcomes reported (either via a validated scale or
author-defined scale; see Table 1). Discrepancies were resolved by
consultation with another reviewer (A.B.). Full-text articles pub-
lished in languages other than English were assessed by research-
trained native speakers working alongside the reviewers to ensure
consistency.
An electronic data formwas used to compile abstracted infor-
mation.MethodologicalqualitywasassessedusingtheCochraneCol-
laboration’sRiskofBias tool15 forRCTsandtheEffectivePublicHealth
PracticeProject (EPHPP) tool16 for nonrandomized studies. Anevi-
dence grade (A-C) and recommendation (I-III) was assigned using
theAmericanHeartAssociation (AHA) scale foreach treatment (see
eBox 2 in the Supplement).17
Both fixed- or random- effects model meta-analysis and a
Bayesian mixed treatment comparison were planned as stipu-
lated in the protocol (PROSPERO CRD42013006642) but were
not performed because of heterogeneity in interventions, trial
populations, reporting, and definitions of outcome measures and
methods. Data were therefore summarized narratively and priori-
tized to emphasize the highest quality of evidence, defined as
randomized clinical trials with a low risk of bias.
Results
The search identified 13 075 titles, of which 222 underwent full
review. Seventy-eight studies (n = 8930 participants) met our
inclusion criteria (see eFigure in the Supplement). Of these, 11 RCTs
were classified as having high within-study risk of bias, mainly
attributable to allocation concealment bias, lack of blinding, incom-
plete outcome data, or selective outcome reporting. Twenty-one
were classified as being at unclear risk of bias, mainly because of
poor reporting and lack of methodological detail. The quality of
case series and nonrandomized studies wasweak (n = 9) ormoder-
ate (n = 2). The remaining 35 RCTs18-52 were at low risk of bias and
are presented below and summarized in eTables 1-3 in the
Supplement (details for all other included studies are summarized
in eTables 4-6 in the Supplement). Evidence grades and recom-
mendations are reported in Table 2.
Treatment
Treatment focuses on relieving symptoms and preventing serious
morbidity such asWernicke encephalopathy, renal impairment, and
extreme weight loss.53-55 Treatments can be categorized into 3
broad yet overlapping groups. First-line treatments, including
simple lifestyle changes (such as eating small amounts often, avoid-
ing dietary triggers and strong odors, eating high-carbohydrate,
low-fat foods) and over-the-counter remedies, such as vitamin B6
(pyridoxine), ginger, and sea bands (an acupressure towelling wrist
band that stimulates the Pericardium P6 acupressure point), are
usually initiated by women when first experiencing symptoms.
Second-line treatments are typically prescribed when a woman
first presents tomedical care, usually by her obstetric care provider,
and include a range of antiemetic drugs as well as provision of intra-
venous fluid and electrolyte replacement for womenwho are dehy-
drated and ketotic. Third-line treatments are reserved for women
Key Points
Question Which interventions are associated with improved
symptoms of nausea and vomiting in pregnancy or hyperemesis
gravidarum?
Findings In this systematic review, ginger, vitamin B6,
antihistamines, metoclopramide (mild symptoms), and
pyridoxine-doxylamine (moderate symptoms) were associated
with improved nausea and vomiting in pregnancy as compared
with placebo. Ondansetron was associated with symptom
improvement for all severity of nausea and vomiting in pregnancy
and hyperemesis gravidarum, and corticosteroids were associated
with beneficial effects in severe cases.
Meaning Both over-the-counter and prescription therapies are
associated with improved symptoms of nausea and vomiting in
pregnancy and hyperemesis gravidarum, although the evidence
supporting these therapies is generally of low quality.
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with severe, persistent symptoms and are initiated in a hospital set-
ting. These include corticosteroids and supportive therapy, such as
enteral feeding. Depending on symptom severity, women may
progress from one category to another or may bypass first-line
treatments. When second- or third-line treatments fail, some
women opt for termination of pregnancy.56,57 An international
online survey carried out by the Hyperemesis Education and
Research Foundation reported that of 808 respondents, 15.2%
stated that they had undergone at least 1 pregnancy termination
for hyperemesis gravidarum.56
First-Line Treatments forMild toModerate Symptoms
Ginger | Ginger (Zingiber officinale) is available in several prep-
arations: powdered fresh root, tablets, capsules, and syrup. Its
antinausea properties were first described in traditional Chinese
medicine.58 Four RCTs compared ginger with placebo, and all
reported an improvement in symptoms from baseline compared
with placebo, regardless of the ginger dose and preparation.18-21
Basirat et al18 (n = 70) reported greater improvement in symptoms
on a visual analog scale (VAS) (participants specify their level of
symptom severity by indicating a position along a continuous line
between 0 [no symptoms] and 10 [worst possible symptoms]; see
Table 1). The ginger group changed from a mean of 5.88 (SD, 1.83)
at baseline to 3.03 (SD, 2.19) on day 4 compared with 4.67 (SD,
1.97) to 3.03 (SD, 2.47) for the placebo group (P = .01), but there
was no difference in episodes of vomiting. Fischer-Rasmussen et
al19 (n = 30) reported that mean nausea and vomiting relief score
(a complex score designed by the authors that takes into account
intensity of nausea, vomiting, weight loss, ketonuria, and hemato-
crit; range not provided), improvedmore for ginger compared with
placebo over two 5-day treatment periods (4.1 vs −0.1 and 3.7 vs
0.9 [P = .035]). Vutyavanich et al20 (n = 70) reported a greater
improvement in VAS scores for nausea (2.1 v 0.9, P = .014) and
vomiting episodes (1.4 v 0, P < .001) in the ginger group compared
with placebo. Similarly, Keating and Chez21 (n = 26) reported
greater improvements in VAS scores for nausea (10 women in the
ginger group had greater than a 4-point improvement compared
with 2 women in the placebo group by day 9), and a greater pro-
portion stopped vomiting in the ginger group (8 women in the
ginger group compared with 2 in the placebo group by day 6,
P value not reported).
Four RCTs compared ginger capsules and vitamin B6.
22-25
Chittumma et al (n = 126)22 and Ensiyeh and Sakineh23 (n = 70)
reported greater improvements in nausea scores in women tak-
ing ginger capsules compared with vitamin B6 (Chittumma et al:
improvement in Rhodes score 3.3 vs 2.5, P < .05; Ensiyeh et al:
change in VAS scores, 2.2 v 0.9, P = .024). Smith et al24 (n = 291)
and Sripramote and Lekhyananda25 (n = 138) found no differ-
ences between the efficacy of ginger and vitamin B6. Sripramote
and Lekhyananda reported improvements in symptoms within
each group via VAS for nausea and episodes of vomiting but no
difference between groups.24,25 Similarly, Biswas et al26 (n = 78)
compared ginger with a doxylamine-pyridoxine combination and
reported symptom improvement within each group via VAS but
no difference between groups. Saberi et al27 (n = 159), reported
that ginger capsules compared with sea bands were associated
with a greater improvement in symptoms (Rhodes score
improvement, 8.61 for ginger and 4.17 for sea bands; P < .001).
In summary, treatment with ginger was associated with im-
provement in mild symptoms (level A, class IIa).
Acupressure, Acupuncture, and Nerve Stimulation | Acupressure
involves the application of physical pressure to specific acupunc-
ture points (eg, the Pericardium 6 [P6] point lies one-sixth of the
distance up the arm from the inner aspect of the wrist between
the 2 tendons; pressure at this point is believed to reduce symp-
toms of nausea and vomiting). Three RCTs compared acupressure
with placebo in women with mild symptoms.28-30 Bayreuther
et al28 (n = 23) and Belluomini et al29 (n = 60) reported improved
symptoms from baseline following acupressure at P6 compared
with pressure at an alternative location. Bayreuther et al reported
improvement in the VAS score for nausea (3.23 in the treatment
group, 4.92 in the placebo group [P = .019]). Belluomini et al
reported improvement in symptoms in both groups but only a
significant improvement for vomiting in the acupressure group
(change in Rhodes score from 2.09 [SD, 2.5] to 1.28 [SD, 1.9]
[P = .03] vs 1.83 [SD, 2.7] to 1.63 [SD, 2.3] [P not reported in the
placebo group]). Naemi-Rad et al30 (n = 80) reported reduced
symptoms of nausea and vomiting after 2 days when comparing
acupressure at acupoint Kidney 21 (KID21, a traditional Chinese
point on the upper abdomen, 6 cm above the umbilicus, 5 cm lat-
eral to the anterior midline) with nonstimulation (median VAS
scores for nausea intensity, 4 [interquartile range {IQR}, 2-5] for
the acupoint group and 7 [IQR, 5-8] for the comparator group
[P < .001]; mean scores for vomiting, 0 [IQR, 0-0.75] and 1 [IQR,
0-2], respectively [P < .001]).
Rosen et al31 (n = 230) compared nerve stimulation with pla-
ceboandreportedagreater improvement in theRhodesscore in the
Table 1. Tools Used toMeasure the Severity of Nausea and Vomiting in Pregnancy
Tool Description Scoring
Maximum
Score
Cut Point
for Severe Symptoms
Pregnancy-Unique
Quantification of Emesis
and Nausea (PUQE
and PUQE 24 score)7-9
Three questions regarding nausea,
vomiting, and retching during previous
12 h (original version) or 24 h
(most commonly used version)
For each question, 0 = no symptoms;
5 = worst possible symptoms
15 Scores ≥13 indicate
severe symptoms
The Rhodes Index of Nausea,
Vomiting and Retching10-12
Eight questions about duration/amount,
frequency, and distress caused by
symptoms of nausea, vomiting,
and retching
For each question, 0 = no symptoms;
5 = worst possible symptoms
40 Scores ≥33 indicate
severe symptoms
Nausea and vomiting of
pregnancy instrument13,14
Three questions relating to nausea,
retching, and vomiting over
the past 7 d
For each component, 0 = no symptoms;
5 = worst possible symptoms
15 Score ≥8 indicates
severe symptoms
Visual analog scale Patients rate their symptoms on a scale
of 0-10
0 = no symptoms; 10 = extreme
symptoms
10 Not applicable
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treatment group (mean change from baseline, 6.48 [95% CI, 5.31-
7.66] vs 4.65 [95% CI, 3.67-5.63] [P = .02]).
Jamigorn and Phupong32 (n = 66) compared 5 days of treat-
ment with acupressure using sea bands plus placebo tablet vs
treatment with bands at nonstimulating position plus vitamin B6
(50 mg twice daily). Both were allowed to take dimenhydrinate
(50 mg every 6 hours as needed). Symptoms improved in each
group, with no difference in improvement between groups. Use of
dimenhydrinate was not different between the groups.
Three RCTs compared acupuncturewith other treatments.33-35
A 4-group RCT conducted by Smith et al33 (n = 593) compared tra-
ditional acupuncture, P6 acupuncture, sham treatment, and an
information brochure. Women receiving traditional and P6 acu-
puncture had less nausea by the third week comparedwith women
in the sham treatment and information-only group (Rhodes Index
nausea component score [range, 0-12; 0 = best], 3.8 in the tradi-
tional acupuncture group; 4.3 in the P6 acupuncture group; 4.4 in
the sham treatment group; and 5.8 in the control group [P = .001]).
No differences in vomiting scores were found between the groups
over the 3-week study period. A crossover trial by Carlsson et al34
(n = 33) reported a reduction in symptoms over time but no dif-
ference between P6 and sham acupuncture in nausea symptoms
Table 2. Grade of Evidence and Recommendation
Treatmenta No. of Studiesb Risk of Bias/Quality AHA Rating
First-Line Treatments for Mild-Moderate Nausea and Vomiting in Pregnancy
Ginger 17 Randomized
clinical trials
10 = low19-27
3 = unclear64-66
4 = high67-70
Level A, class IIa
Acupressure 10 Randomized
clinical trials
5 = low27-30,32
4 = unclear71-74
1 = high75
Level A, class IIa
1 Case series 1 = weak76
Nerve stimulation 3 Randomized
clinical trials
1 = low31
2 = unclear77,78
Level B, class IIb
Acupuncture 6 Randomized
clinical trials
3 = low33-35;
3 = high79-81
Level A, class IIb
Aromatherapy 2 Randomized
clinical trials
2 = unclear82,83 Level B, class IIb
Vitamin B6 (pyridoxine) 14 Randomized clinical
trials
7 = low22-25,32,36,37
4 = unclear65,84-86
3 = high68,69,87
Level A, class IIa
Second-Line Treatments for Moderate-Severe Nausea and Vomiting in Pregnancy or Hyperemesis Gravidarum
Psychotherapy 1 Randomized
clinical trial
1 = low42 Level B, class IIa
Vitamin B6 (pyridoxine)/doxylamine
combination
5 Randomized
clinical trials
4 = low26,38-40
1 = unclear88
Level A, class IIa
1 Case-control study
1 Cohort-analytic
1 = weak89
1 = moderate90
Antihistamines 7 Randomized
clinical trials
1 = low41
4 = unclear66,86,91,92
2 = high87,93
Level B, class IIa
Dopamine antagonists 10 Randomized
clinical trials
5 = low43-45,50,51
3 = unclear94-96
2 = high70,79
Level A, class IIa
1 Case-control study
1 Cohort study
1 = weak89
1 = weak97
Serotonin antagonists 7 Randomized
clinical trials
3 = low39,44,45
4 = unclear88,91,92,94
Level A, class IIa
1 Cohort analytic study 1 = weak98
Intravenous fluids 1 Randomized
clinical trial
1 = low46 Level B, class IIa
Intravenous fluids
with or without diazepam
1 Randomized
clinical trial
1 = unclear99 Level B, class III
Outpatient/day-case management 2 Randomized
clinical trials
1 case series study
2 = low47,48
1 = weak100
Level A, class IIa
Third-Line Treatments for Moderate-Severe Nausea and Vomiting in Pregnancy or Hyperemesis Gravidarum
Corticosteroids 6 Randomized
clinical trials
3 = low49-51
2 = unclear95,96
1 = high101
Level A, class IIb
1 Case series 1 = weak102
Nasogastric/assisted feeding 2 Case series
1 Cohort analytic
2 = weak103,104
1 = moderate105
Level C, class IIb
Gabapentin 1 Case series 1 = weak106 Level C, class III
Transdermal clonidine 1 Randomized
clinical trial
1 = low52 Level B, class IIb
Abbreviation: AHA, American Heart
Association.
a Includes treatments excluded from
the narrative summary due to the
particularly low quality of available
evidence (aromatherapy,
intravenous fluids with or without
diazepam, gabapentin, and
nasogastric/assisted feeding.
bNumber of studies includes all those
with an appropriate treatment
group (either intervention or
comparator).
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after a 6-day treatment period.3 A similar outcome was found by
Knight et al35 (n = 56) (median final VAS score [range, 0 {no symp-
toms} to 100 {worst possible symptoms}] for nausea 3 days after
session 4, 47.5 [IQR, 29.25-69.5] for P6 acupuncture vs 48.0 [IQR,
14.0-80.0] for sham treatment).
In summary for acupressure: treatment with acupressure was
associated with symptom improvement for mild cases (level A,
class IIa).
Fornervestimulation:evidence indicates treatmentmaybecon-
sidered, but the benefit was unclear (level B, class IIb).
For acupuncture: the benefit was unclear (level A, class IIb).
Vitamin B6 (Pyridoxine) | Two RCTs examined the association of vi-
taminB6with improvement inpeoplewithmild tomoderate symp-
toms. Vutyavanich et al36 (n = 342) compared vitamin B6 (1 mg 3
times daily)with placebo. VitaminB6was associatedwith a greater
reduction inmean nausea VAS score from baseline comparedwith
aplacebo tablet (2.9 [SD, 2.2] vs2.0 [SD, 2.7] [P < .001]). Therewas
no difference in reported vomiting.36When high- and low-dose vi-
tamin B6 (10 mg vs 1.28 mg daily) were compared in 60 women, a
greater change in Pregnancy-Unique Quantification of Emesis and
Nausea (PUQE) score (3-question scale, scoring from 0 [no symp-
toms] to 15 [worst possible symptoms]; see Table 1) was reported
in the high-dose group (mean change, 3.86 [SD, 2.12] in the high-
dose group, 2.80 [SD, 1.78] in the low-dose group [P < .05]).37
In summary, treatment with vitamin B6 was associated with
symptom improvement for mild cases (level A, class IIa).
Second-Line Treatments forModerate-Severe Symptoms
VitaminB6 (Pyridoxine)/DoxylamineCombination |ThreeRCTscom-
pared pyridoxine-doxylamine combinationswith either placebo or
ondansetron.Korenet al38 (n = 280) comparedpyridoxine (10mg)
plusdoxylamine(10mg,slow-releasepreparation)withplaceboover
14 days. Symptoms improved in both groups, but the improve-
ment in thepyridoxine-doxylaminegroupwasgreater (meanchange
in PUQE score, 4.8 v 3.9; P = .006).
Oliveira et al39 (n = 36) compared pyridoxine-doxylamine
with ondansetron. Symptom improvement occurred in both
groups but was greater in the ondansetron group (median change
using a 0-100 VAS for nausea: 51 [IQR, 37-64] for ondansetron, 20
[IQR, 8-51] for pyridoxine-doxylamine [P = .019]; vomiting: 41
[IQR, 17-57] for ondansetron, 17 [IQR, 4-38] for pyridoxine-
doxylamine [P = .049]). Maltepe and Koren40 (n = 60) compared
preemptive treatment with pyridoxine-doxylamine vs treatment
once symptoms started. Moderate-severe symptoms were
reduced in the preemptive group (15.4%) compared with the post-
symptom group (39.1%) (P < .04).
In summary, treatment with vitamin B6 (pyridoxine)–
doxylaminewasassociatedwithsymptomimprovement forwomen
with mild-moderate symptoms (level A, class IIa).
Erez et al41 (n = 150) compared hydroxyzine hydrochloride
(25 mg twice daily for 3 weeks) with placebo. Symptom improve-
ment occurred in the treatment group with partial or complete re-
lief of symptoms in82%ofwomen, comparedwithonly 22% in the
placebo group (P < .01).
In summary, limited-quality evidence indicated that treatment
with antihistamineswas associatedwith symptom improvement in
mild-moderate cases (level B, class IIa).
Psychotherapy |AnRCTbyFaramarzi et al42 (n = 86)comparedpsy-
chotherapytreatmentwithstandardcare.Allwomenreceived40mg
of vitamin B6 daily, and the treatment group received eight 50-
minute psychotherapy sessions over a 3-week period. A greater
change in themean Rhodes scorewas seen in the treatment group
(18.76 [SD, 5.48] to 7.06 [SD, 5.79] vs 19.18 [SD, 5.63] to 12.81 [SD,
6.88], P < .001).
In summary forpsychotherapy: limitedevidence indicated that
psychotherapyplus vitaminB6was associatedwith greater benefit
than vitamin B6 alone (level B, class IIa,).
Dopamine Antagonists | Tan et al43 (n = 159) compared metoclo-
pramide (10mg)with promethazine (25mg) given intravenously 3
timesover24hours. Symptoms improved inboth treatmentgroups,
with no difference between groups (episodes of vomiting, 1 [IQR,
0-5] formetoclopramidevs2 [IQR,0-3] for promethazine [P = .81],
VAS [0-10 scale] for nausea, 2 [IQR, 1-5] vs 2 [IQR, 1-4], respectively
[P = .99]).
In summary, evidence indicated that treatment with dopa-
mine receptor antagonists was associated with improved symp-
toms (level A, class IIa).
Serotonin Antagonists (Ondansetron) | TwoRCTs compared ondan-
setron withmetoclopramide. Abas et al44 (n = 160) compared on-
dansetron (4mg intravenously)withmetoclopramide (10mg intra-
venously). Symptom improvement was seen in both groups, with
no evidence of difference between groups at 24 hours. However,
more women in the metoclopramide group reported adverse ef-
fects (drowsiness: 12.5% for ondansetron vs 30% for metoclo-
pramide [P = .011]; dry mouth: 10% for ondansetron vs 23.8% for
metoclopramide (P = .03). Kashifard et al45 (n = 83) compared on-
dansetronwithmetoclopramideover2weeks.Ondansetronwasas-
sociated with lower nausea scores on day 4 than metoclopramide
(meanvisual analog scale [VAS] score, 4.1 [SD, 2.9] for ondansetron
vs 5.7 [SD, 2.3] formetoclopramide [P = .023]) but not episodes of
emesis (5.0 [SD, 3.1] vs 3.3 [SD, 3], respectively [P = .013]). The on-
dansetron group had lower vomiting scores than the metoclo-
pramide group calculated over 14 days (P = .042, rawdata not pro-
vided), but there was no difference in trend in nausea scores over
14 days between groups.
In summary, treatmentwithserotonin receptorantagonistswas
associatedwith improvement in symptomsof all severities (levelA,
class IIa).
Intravenous Fluids | Tan et al46 (n = 222) compared different com-
positions of intravenous solution. The intervention group received
intravenousdextrosesalinewithantiemeticsaccordingtohealthcare
provider preference, whereas the comparator group received nor-
mal saline with antiemetics. Repeated-measures analysis of vari-
ance of nausea score found greater improvements in the dextrose
saline group relative to the saline group (P = .046), but no differ-
ence in vomiting was reported.
Insummary, limitedevidence indicatedthatdextrosesalinemay
be associated with better improvements than normal saline in
moderate-severe cases (level B, class IIa).
Outpatient/Day-Case Management | Two RCTs compared day-care
outpatient management with inpatient care.47,48 McParlin et al47
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(n = 53) reported no difference in symptom severity over 7 days
between women who received outpatient rehydration and an
antiemetic (cyclizine, 50 mg intravenous/oral) vs inpatient care.
McCarthy et al48 (n = 98) also compared outpatient with inpa-
tient care. The median number of nights spent in the hospital was
lower in the outpatient group (0 [IQR, 0-2] vs 2 [IQR, 1-4] nights,
P < .001).
In summary, evidence indicated that outpatient treatmentwas
associated with benefits that are not better or worse than inpa-
tient intravenoustherapy inpatientswithmoderatesymptoms(level
A, class IIa).
Third-Line Treatments forModerate-Severe Symptoms
Corticosteroids | Three RCTs compared corticosteroids with pla-
cebo or other treatments. Nelson-Piercy et al49 (n = 40) com-
pared prednisolonewith placebo. Therewas no difference in vom-
itingandnauseascores in thesteroidgroupcomparedwithplacebo.
Safari et al50 (n = 40) compared methylprednisolone with pro-
methazine. Therewas nodifference in symptom improvement by 1
week. However, no patients from the methylprednisolone group
were readmitted for recurrence of vomiting, compared with 5 pa-
tients from the promethazine group (P < .01).
Bondok et al51 (n = 40) compared hydrocortisone with meto-
clopramide. Steroids were associated with a greater reduction in
vomiting episodes comparedwithmetoclopramide (emesis reduc-
tion, 40.9% vs 16.5% at day 2; 71.6% vs 51.2% at day 3; 95.8% vs
76.6% at day 7 [n = 40, P < .001]).
In summary, evidence indicated that benefits of corticoste-
roids were unclear. Treatment may be considered in severe cases
(level A, class IIb)
Transdermal Clonidine | Transdermal clonidine patcheswere investi-
gated in 1 randomized crossover trial by Maina et al52 (n = 12) in pa-
tients unresponsive to other antiemetics. Either clonidine or placebo
patcheswerewornfor5daysbeforethetreatmentwasalternated. In-
travenous fluids and rescue antiemetics were given as required. The
meanimprovement insymptomscoreswasgreaterforclonidinetreat-
ment (mean PUQE score, 6.3 [95% CI, 5.5-7.1] for clonidine and 8.5
[95%CI, 7.7-9.3] for placebo, P = .001), and therewas less use of an-
tiemetics and intravenous therapy in the clonidine group.
In summary, limited evidence indicated treatment with trans-
dermal clonidinewasassociatedwith symptom improvements, but
currently this is not an established treatment for nausea and vom-
iting in pregnancy in clinical practice (level B, class IIb).
Table 3. Dose, CommonAdverse Effects, and Contraindications of Recommended Therapies by Severity of Nausea and Vomiting of Pregnancy
and Hyperemesis Gravidaruma
Therapy Dose Adverse Effects Contraindications
Mild Symptoms
Ginger Most common regime: 250 mg
every 6 h
Acid reflux None apparent
Vitamin B6 (pyridoxine) 10-25 mg every 8 h Drowsiness; decreased sensation to
touch, temperature, and vibration;
loss of balance or coordination
Antihistamines (eg, cyclizine) 50 mg every 8 h Drowsiness; dizziness; muscle
twitches; dry mouth; headache; rash;
tachycardia
Glaucoma, high or low blood pressure,
epilepsy
Moderate Symptoms
Antihistamine/vitamin B6
combination
(doxylamine/pyridoxine)
10 mg doxylamine + 10 mg pyridoxine
up to 4 times daily if needed
Drowsiness; somnolence; dizziness;
nervousness; stomach pain; headache;
diarrhea; irritability; insomnia
Taking monoamine oxidase inhibitors,
antimuscarinic drugs
Metoclopramide 10 mg every 8 h Dystonic movements; oculogyric
crises; diarrhea; drowsiness;
restlessness; irritability; dry mouth;
insomnia; urinary problems;
depression; rash
Kidney or liver disease, congestive heart
failure, high blood pressure, diabetes,
history of depression, epilepsy (or other
seizure disorder)
Promethazine 25 mg every 8 h Dizziness; drowsiness; excitation;
rash; increased sensitivity of skin to
sunlight; lack of coordination; loss of
strength or energy; muscle pain or
weakness; insomnia
Should be used with caution in persons with
seizure disorders or in persons using
concomitant medications, such as narcotics
or local anesthetics, which may also affect
seizure threshold
Ondansetron 4 mg every 8 h Anxiety; dizziness; constipation; dry
mouth; confusion, headache;
hyperventilation; tachycardia;
irritability; restlessness; muscle
spasms; insomnia
Cardiac arrhythmias, history of prolonged
QT interval, heart failure, hypokalaemia,
hypomagnesemia, use of concomitant
medications that lead to prolongation of QT
interval
Severe Symptoms
Ondansetron 4-8 mg every 8 h Anxiety; dizziness; constipation; dry
mouth; confusion, headache;
hyperventilation; tachycardia;
irritability; restlessness; muscle
spasms; insomnia
Cardiac arrhythmias, history of prolonged
QT interval, heart failure, hypokalaemia,
hypomagnesemia, use of concomitant
medications that lead to prolongation of QT
interval
Corticosteroids Hydrocortisone (100 mg intravenously
twice daily) converting to oral
prednisolone (40-50 mg daily), with
the dose gradually tapered until the
lowest maintenance dose is reached
Increased risk of infections;
gestational diabetes mellitus
Systemic infections, unless specific
anti-infective therapy is used
Live virus immunization
Hypersensitivity to any component
a Data obtained from searches of appropriate drug and therapeutic websites.
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Discussion
The review found low-quality evidence for therapies treating nau-
sea and vomiting in pregnancy and hyperemesis gravidarum. Less
than half of all studies were judged as being at low risk of bias.
Ginger, acupressure, andvitaminB6areappropriate initial over-
the-counter therapies for mild symptoms. Treatment with nerve
stimulationmay be considered, but, aswith acupuncture, the ben-
efit is unclear.
When symptoms are mild-moderate, or if the above over-the-
counter therapieswerenotbeneficial, antihistamines (aloneorcom-
bined with vitamin B6) were associated with improved symptoms
comparedwith placebo. Limited evidence indicated an association
between psychotherapy, metoclopramide, and promethazine and
improvements in moderate symptoms. There was no evidence to
indicate that these treatments are unsafe, but more research is
needed.
Whensymptomsaremoderate-severe,outpatient,day-careman-
agement is feasible, acceptable, and does not result in worse out-
comescomparedwith inpatientcare.Theserotonin receptorantago-
nist ondansetron improves symptoms at all severities, but benefit
comparedwithmetoclopramideorantihistamines isunclear.Ondan-
setronappears tobesafe inpregnancy,59butevidence is limitedand
more research is needed. Large doses of intravenous ondansetron
(morethan8mgin1 intravenousdose)arecontraindicated inwomen
at risk of cardiac arrhythmias (QT prolongation). In such circum-
stances, an electrocardiogram should be performed and electrolyte
levelscheckedprior totreatment.60There isnoevidencethatoralad-
ministration of ondansetron causes QT prolongation in adults.10
When symptoms are more severe or persistent, corticoste-
roids are associated with improved symptom severity and may be
more beneficial than metoclopramide and promethazine. How-
ever,use isgenerally limitedtowomenwithsevere intractablesymp-
tomswith prior treatment failure, preferably after 10weeks’ gesta-
tion and during an inpatient admission. This arises from concerns
regarding a small increase in incident oral clefts in fetuses exposed
to corticosteroids in utero in pooled data from observational
studies.61Moreevidence is neededcomparing corticosteroidswith
other medications.
ComparisonWith Previous Literature
The American College of Obstetricians and Gynecologists pub-
lishedclinicalmanagementguidelines inAugust2015,2 recommend-
ing the use of vitamin B6 or vitamin B6 plus doxylamine as first-line
pharmacotherapy,gingerasanonpharmacologicaloption,andmeth-
ylprednisolone in refractorycases.Recommendationsbasedoncon-
sensus include intravenous hydration and enteral tube feeding for
womenwhoarenot responsive tomedical therapy.Manyof the find-
ings in this reviewsupport recommendations in theguidelines.How-
ever, althoughpyridoxineplusdoxylaminewasmoreeffective than
placebo, there is no substantial evidence to suggest that the com-
bination ismore effective than other antiemetics such as antihista-
mines. Moreover, this review adds value by categorizing therapies
depending on symptomseverity. TwoCochrane reviewswerepub-
lished recently.62,63 Matthews et al62 included only RCTs focusing
on nausea and vomiting and excluded trials involving hyperemesis
gravidarum; the review by Boelig et al63 only included RCTs of hy-
peremesis gravidarum. Neither review categorized therapies de-
pendingon symptomseverity.However, both reviewswere consis-
tent inconcludingthat there is littlegood-qualityevidencetosupport
any available intervention.
Limitations
These recommendations are limited by the quality and heteroge-
neity of evidence. Quality was downgraded due to clinical hetero-
geneity, imprecision, sparseness of data, or a combination of these
factors. There was also considerable variation in the initial assess-
ment and subsequent reporting of nausea, vomiting, andother rel-
evant outcomes in the identified studies. As a result, we were un-
able to conduct theplannedmeta-analysis stipulated inouroriginal
protocol.
One set of outcomemeasures likely tobe important towomen
andpractitioners is safety.Wesought toassembledataon fetal out-
comes and adverse events; however, no reliable safety data were
identified in the included studies. Details of common adverse ef-
fects of the interventions recommended by this review are pro-
vided inTable3, alongwithcommondosage regimens.Availableob-
servational data (pregnancy-relatedbutnot specifically focusedon
nausea andvomiting) doesnot provide evidenceof any safety con-
cernswith antiemeticmedications; this is not the sameas rulingout
any important differences in adverse outcomes.
Conclusions
Formild symptomsofemesis andnauseaofpregnancy, ginger, pyri-
doxine, antihistamines, andmetoclopramidewere associatedwith
greater benefit thanplacebo. Formoderate symptoms, pyridoxine-
doxylamine, promethazine, and metoclopramide were associated
withgreaterbenefit thanplacebo.Ondansetronwasassociatedwith
symptom improvement for a range of symptom severity. Cortico-
steroidsmaybeassociatedwithbenefit in severe cases.Overall, the
quality of evidence was low.
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